- Home
- LIQT vs AKTX Comparison
LIQT vs AKTX Comparison
Compare LIQT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- AKTX
- Stock Information
- Founded
- LIQT 2004
- AKTX N/A
- Country
- LIQT Denmark
- AKTX United States
- Employees
- LIQT N/A
- AKTX N/A
- Industry
- LIQT Industrial Machinery/Components
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- AKTX Health Care
- Exchange
- LIQT Nasdaq
- AKTX Nasdaq
- Market Cap
- LIQT 21.1M
- AKTX 17.2M
- IPO Year
- LIQT N/A
- AKTX N/A
- Fundamental
- Price
- LIQT $2.00
- AKTX $0.47
- Analyst Decision
- LIQT Strong Buy
- AKTX Strong Buy
- Analyst Count
- LIQT 1
- AKTX 2
- Target Price
- LIQT $3.60
- AKTX $3.30
- AVG Volume (30 Days)
- LIQT 10.4K
- AKTX 468.9K
- Earning Date
- LIQT 11-13-2025
- AKTX 11-13-2025
- Dividend Yield
- LIQT N/A
- AKTX N/A
- EPS Growth
- LIQT N/A
- AKTX N/A
- EPS
- LIQT N/A
- AKTX N/A
- Revenue
- LIQT $16,788,295.00
- AKTX N/A
- Revenue This Year
- LIQT $36.89
- AKTX N/A
- Revenue Next Year
- LIQT $16.33
- AKTX N/A
- P/E Ratio
- LIQT N/A
- AKTX N/A
- Revenue Growth
- LIQT 10.97
- AKTX N/A
- 52 Week Low
- LIQT $1.34
- AKTX $0.47
- 52 Week High
- LIQT $3.35
- AKTX $2.45
- Technical
- Relative Strength Index (RSI)
- LIQT 35.35
- AKTX 28.72
- Support Level
- LIQT $2.09
- AKTX $0.60
- Resistance Level
- LIQT $2.35
- AKTX $0.65
- Average True Range (ATR)
- LIQT 0.15
- AKTX 0.07
- MACD
- LIQT -0.04
- AKTX -0.02
- Stochastic Oscillator
- LIQT 4.35
- AKTX 1.98
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.